Nonobese diabetic (NOD) mice develop spontaneous autoimmune diabetes, particularly in females. Lymphocytes begin to infi ltrate the pancreatic islets between 4 and 9 wk of age, whereas overt diabetes caused by destruction of insulin-producing β cells (defi ned by the inability to maintain normal blood glucose levels) does not occur until 11-25 wk of age. Many treatments are able to prevent diabetes in NOD mice when given weeks before diabetes develops (1) . However, few treatments have been found that can inhibit diabetes development at the time of onset or reverse diabetes after hyperglycemia is observed (2) (3) (4) (5) (6) . These two later pathogenic stages parallel potential intervention points in human type 1 diabetes. Identifying tolerance mechanisms that work at these points is important both for understanding the disease and for translating fi ndings into clinical studies and results. In humans, antigen nonspecifi c anti-CD3 has been used with some effi cacy (2, 7) . Adding antigen specifi city may improve treatment, and this issue is beginning to be addressed in mouse models, where treatment of diabetes is seen with lower doses of anti-CD3 if given along with islet peptides (6) .
Recently, we have shown that antigenpulsed DCs and IL-2 can expand functional antigen-specifi c T reg cells (8) (9) (10) . To study T reg cells in the context of NOD mice, we have used CD4 + CD25 + TCR transgenic T cells from the BDC2.5 line (11) . BDC2.5 T cells recognize a peptide that mimics an unidentifi ed natural antigen in islet β cells (12) . DC-expanded, BDC2.5 islet-specifi c T reg
Most treatments that prevent autoimmune diabetes in nonobese diabetic (NOD) mice require intervention at early pathogenic stages, when insulitis is fi rst developing. We tested whether dendritic cell (DC)-expanded, islet antigen-specifi c CD4 + CD25 + suppressor T cells could treat diabetes at later stages of disease, when most of the insulin-producing islet cells had been destroyed by infi ltrating lymphocytes. CD4 + CD25 + CD62L + regulatory T cells (T reg cells) from BDC2.5 T cell receptor transgenic mice were expanded with antigenpulsed DCs and IL-2, and were then injected into NOD mice. A single dose of as few as 5 × 10 4 of these islet-specifi c T reg cells blocked diabetes development in prediabetic 13-wk-old NOD mice. The T reg cells also induced long-lasting reversal of hyperglycemia in 50% of mice in which overt diabetes had developed. Successfully treated diabetic mice had similar responses to glucose challenge compared with nondiabetic NOD mice. The successfully treated mice retained diabetogenic T cells, but also had substantially increased Foxp3 + cells in draining pancreatic lymph nodes. However, these Foxp3 + cells were derived from the recipient mice and not the injected T reg cells, suggesting a role for endogenous T reg cells in maintaining tolerance after treatment. Therefore, inoculation of DC-expanded, antigen-specifi c suppressor T cells has considerable effi cacy in ameliorating ongoing diabetes in NOD mice.
cells are >100-fold more potent in preventing diabetes than T reg cells derived from a polyclonal NOD T cell repertoire, indicating the importance of antigen specifi city for T reg cell function (9) . Islet-specifi c BDC T reg cells can also be expanded using beads coated with either mitogenic antibodies or tetramers, but it has not been determined if these beadexpanded T reg cells express high levels of Foxp3 protein (a transcription factor important for T reg cell function [13] ) or if these cells are as potent as DC-expanded T reg cells for inhibition of diabetes (14, 15) .
In some instances, islet-specifi c T reg cells have been shown to treat later stages of diabetes. In one experiment, in addition to treatment with T reg cells, islet transplant was used to rescue insulin production (14) . In another experiment, the T reg cells were artifi cially induced by transfecting the T cells with Foxp3 (16) . Both of these systems have drawbacks for potential translation into human therapy, the former because of the limited availability of islets for transplantation and the later because of the demands of human gene therapy. Therefore, it is important to establish the efficacy of naturally occurring islet-specifi c T reg cells in a cell therapy model and to use these cells without the addition of other demanding strategies.
In this study, we show that DC-expanded, islet-specifi c T reg cells can block diabetes months after initiation of insulitis and restore long-term normoglycemia when given to recent-onset diabetic mice. When compared with untreated diabetic controls, the diabetic mice successfully treated with T reg cells respond better in a glucose tolerance test and have increased numbers of Foxp3 + cells when compared with untreated diabetic mice. Interestingly, the Foxp3 + cells in treated mice are not from the injected T reg cells but derive from the recipient T cell repertoire.
RESULTS
After expansion with DCs, CD4 + CD25 + CD62L + cells from BDC2.5 mice retain high Foxp3 and CD62L expression and divide in the pancreatic lymph node Previously, we showed that bone marrow-derived DCs loaded with cognate peptide were eff ective at inducing expansion of CD4 + CD25 + T cells (8, 9) . In this study, we further separated this population before expansion, according to expression of the lymph node homing and memory/activation marker CD62L, into CD4 + CD25 + CD62L + and CD4 + CD25 + CD62L − (Fig. 1 A) . CD62L + cells can home to lymph nodes, which may be important for T reg cell function (17, 18) . After expansion with DCs, the majority of CD62L + cells maintained high levels of CD62L and Foxp3. DCexpanded CD62L − T cells expressed similar levels of Foxp3 but lower CD62L when compared with the CD62L + cells (Fig. 1, B and C) .
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BDC2.5 T cells proliferate and expand in the pancreatic lymph node, but not other lymph nodes (14, 19) , most likely because antigens from islet β cells are presented by DCs in the draining pancreatic lymph node (20) . To check the in vivo activity of DC-expanded CD4 + CD25 + cells, these cells were labeled with carboxyfl uorescein diacetate succinimidyl ester (CFSE) and transferred into NOD mice. BDC2.5 T cells were followed using a clonotype anti body specifi c for the BDC2.5 TCR. 10 d later, few BDC clonotype + cells remained in the peripheral lymph nodes, and most had not diluted CFSE. In contrast, in the pancreatic lymph node, clonotype + T cells accumulated, and a substantial fraction had undergone one or more divisions, as indicated by lower CFSE fl uorescence (Fig. 1 D) . Therefore, like conventional T cells, the DC-expanded T reg cells home to and proliferate in antigen-draining lymph nodes, presumably in response to DCs presenting cognate antigen (21) .
Some previous studies have shown that the number of T reg cells in NOD mice decreases with age (22, 23 ). An impaired ability of T reg cells to proliferate in vivo is one explanation to account for this observation. Other studies have observed constant numbers of T reg cells in diff erent ages of NOD female mice (22, 24) . In our observation, the ability of the DC-expanded BDC T reg cells to proliferate in response to antigen in the pancreatic lymph node did not substantially alter with the age of the host. At 5 wk, which correlates with the onset of insulitis, and at 12 wk, which correlates with onset of destructive diabetes, similar levels of CFSE dilution were observed (Fig. 1 D) . Therefore, no alteration in environment occurs in the pancreatic lymph node during diabetes pathogenesis that inhibits the ability of T reg cells to proliferate.
Islet-specifi c T reg cells block spontaneous diabetes when given just before the time of diabetes onset We tested whether these islet-specifi c T reg cells from BDC2.5 mice were eff ective at blocking the development of spontaneous diabetes in 13-wk-old female NOD mice. This time point is late in the pathogenic process, when diabetes begins and islet infl ammation has usually progressed for at least 6 wk (25) . We found that one dose of 3 × 10 5 DC-expanded BDC2.5 CD4 + CD25 + CD62L + T cells could signifi cantly delay diabetes when given at 13 wk; mice receiving these cells only began to slowly develop diabetes after 30 wk. In contrast, the CD4 + CD25 + CD62L − population had no eff ect (Fig. 2 A) . In a second prevention experiment, smaller numbers of DC-expanded CD4 + CD25 + CD62L + cells from BDC2.5 mice were given to prediabetic mice. Groups receiving 2 × 10 5 , 5 × 10 4 , or 10 4 cells had a signifi cant delay in diabetes. Again, DCexpanded CD4 + CD25 + CD62L − cells had no eff ect on diabetes development (Fig. 2 B) . In addition, CD62L + T reg cells from NOD mice expanded with DCs and anti-CD3 were not able to inhibit diabetes development (Fig.  2 C) , showing the need for islet-antigen specifi city for tolerance induction, as observed in the NOD.scid transfer model (9) . Therefore, small numbers of islet-specifi c CD62L + T reg cells can block diabetes when given just before the mice normally develop diabetes. 
Treatment of diabetic mice with islet-specifi c T reg cells
We next turned to newly diabetic mice with elevated blood glucose levels. We determined the eff ectiveness of using a combination of islet-specifi c T reg cells and short-term insulin replacement using insulin pellets, which release insulin for ‫3ف‬ wk. In addition, we used the gut-derived glucagon-like peptide 1 (GLP-1), which stimulates insulin secretion (26) and lowers circulating glucose levels in type 2 diabetes patients and healthy human subjects (27, 28) . Recently, it has been reported that GLP-1 promotes the growth and survival of the pancreatic β cells and decreases the metabolic requirement for insulin secretion (29) .
In the fi rst treatment experiment, recent-onset diabetic NOD mice were given insulin and GLP-1 for 3 wk to maintain normal glucose levels, while the induction of immune tolerance by the injected suppressor T cells takes place. Groups were matched for the range of starting blood glucose. In all four control mice that received GLP-1 but not T reg cells, the blood glucose rose again soon after exogenous insulin was not available. In contrast, in three 
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out of fi ve mice that received T reg cells and GLP-1, the blood glucose readings stayed below 200 mg/dL for an additional 90 d (Fig. 3 A) .
Because of a concern of potential residual exogenous insulin secretion from the pellets after the presumed cessation of its release at the 3-wk interval, insulin pellets were removed after 40 d in subsequent experiments. In addition, exendin-4, a more stable analogue of GLP-1, was given i.p. where indicated (30) . Similar results to the ones shown in Fig. 3 A were obtained (Fig. 3 D and Fig. S1 , available at http://www.jem.org/cgi/content/full/jem.20061631/DC1). To determine the importance of adding exendin-4, recentonset diabetic mice were given T reg cells alone or T reg cells and exendin-4. T reg cells alone could restore normoglycemia (Fig. 3, B and D) . In our colony, diabetic NOD mice given no treatment do not become normoglycemic for long periods of time. An example of blood glucose levels from one cohort of NOD female mice followed from 12-25 wk is shown in Fig. S2 .
Interestingly, mice successfully treated with T reg cells and exendin-4 started the experiment with a statistically signifi cant lower mean level of initial blood glucose than those mice in which the same treatment failed; responders had a mean level of 365 mg/dl as compared with 467 mg/dl for nonresponders (Fig. 3 C) . This suggests that the amount of residual β cell mass may be limiting the ability to treat diabetic mice via immune tolerance. Because groups were matched for initial blood glucose, as expected, mice given exendin-4 alone had the same mean initial blood glucose level (421 mg/dl) as mice given T reg cells and exendin-4 (including responders and nonresponders).
In all, a total of 41 mice were followed long term after treatment, and 14 out of 30 mice receiving T reg cells were successfully treated, whereas all 11 mice that did not receive T reg cells failed to maintain long-term normoglycemia (Fig.  3 D and not depicted) . We conclude that diabetes can be reversed after onset by treatment with a combination of CD4 + CD25 + CD62L + T reg cells from BDC2.5 mice and insulin, with or without GLP-1 receptor agonists.
Characterization of insulin response to glucose challenge and insulitis in T reg cell-treated mice
Maintenance of normoglycemia among diabetic mice treated with insulin, GLP-1, and islet-specifi c T reg cells suggests some restoration of β cell function. One measure of β cell function that has been shown to correlate with β cell mass is a glucose tolerance test: determining the time for mice to return to baseline blood glucose levels after i.p. glucose injection; better β cell function (and greater β cell mass) correlates with a faster response (31) . We compared T reg cell-treated mice with three control groups: 12-15-wk-old nondiabetic, 30-wk-old nondiabetic, and recently diabetic NOD mice. The younger nondiabetic control mice exhibit a faster insulin response, as indicated by a more rapid return of blood glucose levels to baseline, than either the older nondiabetic or diabetic control mice. The response in the T reg cell-treated mice was similar to the prediabetic mice; one example of each group is shown in Fig. 4 A. This response can be represented by the area under the curve: a more rapid response corresponding to increased insulin secretion will provide a lower area. When summarized over numerous experiments, the response of T reg cell-treated mice to glucose challenge was signifi cantly lower than the diabetic controls and not signifi cantly diff erent from 12-15-wk-old prediabetic NOD females (Fig. 4 B) , suggesting that the treated mice regained the ability to secrete enough insulin to control the elevated glucose levels that occur after feeding, potentially via increased β cell mass.
The level of insulitis in DC-expanded T reg cell-treated mice was also compared with diabetic or 12-15-or 30-wkold nondiabetic NOD females. In all groups, a mix of healthy and infi ltrated islets was observed (Fig. S3 , available at http://www.jem.org/cgi/content/full/jem.20061631/DC1). Comparable lymphocytic infi ltrates were found in the salivary glands of all mice tested (unpublished data).
Islet-specifi c T reg cell-treated mice contain both pathogenic cells and increased T reg cells
Successfully treated mice were further characterized to look for phenotypes that correlate with treatment. Foxp3 is a transcription factor that can be used to identify T reg cells, especially in infl ammatory conditions where some CD4 + CD25 + cells are recently activated T cells (13) . Both the percentage of CD4 + cells that were Foxp3 + and the total number of Foxp3 + CD4 + T cells was signifi cantly higher in lymph nodes of T reg cell-treated mice as compared with 12-15-wk-old NOD females, either diabetic or nondiabetic. This diff erence was especially pronounced in the draining pancreatic lymph node, where the T reg cell-treated mice had as high as 30% Foxp3 + cells within the CD4 + T cell population. The mean percentage was 25% in treated mice as compared with 15% in diabetic or 14% in nondiabetic controls (Fig. 5 , A and B; and not depicted).
To determine if pathogenic T cells were still present in the treated mice, spleen cells from treated mice were transferred to NOD.scid mice, and diabetes development was followed. Mice injected with spleen cells from diabetic control mice developed diabetes between 30 and 80 d after transfer, and NOD.scid mice injected with spleen cells from T reg cell-treated mice developed diabetes in a similar timeframe (Fig. 5 C) . Therefore, mice successfully treated with DCexpanded T reg cells retain pathogenic cells capable of causing diabetes but also have increased numbers of T reg cells.
Foxp3 + cells in mice successfully treated with T reg cells derive from the diabetic recipient
To determine whether the increase in Foxp3 + cells was caused by the expansion of injected cells, we injected DCexpanded T reg cells from BDC NOD Thy1.1 mice and exendin-4 into diabetic NOD Thy1.2 mice according to the treatment protocol described in Fig. 3 B. 10 d after the insulin pellets were removed, mice that responded to T reg cell treatment (with blood glucose levels >250 mg/dl) were characterized for expression of Thy1.1 and Foxp3. However, in those treated mice almost none of the CD4 + Foxp3 + cells in lymphoid organs were Thy1.1 + , and CD4 + T cells in the pancreas of treated mice were Thy1.1 − , indicating that they derived from the diabetic host and not the injected T reg cells (Fig. 6, A and B; and not depicted). In a similar experiment, no notable population of Thy1.1 T cells was found at a later time point after successful treatment with Thy1.1 + T reg cells (unpublished data). As a positive control, DC-expanded CD62L + or CD62L − T reg cells from BDC2.5 Thy1.1 mice were injected into prediabetic NOD Thy1.2 mice. After 1 wk, CD4 + Thy1.1 + T cells could be found in both the pancreatic lymph node and the pancreas (Fig. 6, C and D) . In addition, pancreas sections from Thy1.2 + diabetic mice treated with Th1.1 + T reg cells were stained with antibodies 
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specifi c for CD4, Foxp3, and Thy1.1, and numerous CD4 + Foxp3 + Thy1.1 − cells were found in the lymphocytic infi ltrate (Fig. 6 E) . As a positive control for Thy1.1 staining, the lymph node from a Thy1.1-expressing mouse was stained with the same antibodies ( Fig. 6 F) ; isotype control staining gave minimal signals in all channels (not depicted). Therefore, during long-term successful treatment, the donor T reg cells can no longer be found in the recipients, even at the disease sites.
We also depleted Thy1.1 + cells from two mice that had been successfully treated with Thy1.1 + T reg cells. This treatment did not lead to diabetes, because blood glucose levels did not substantially change for 7 wk after depletion (Fig.  S4 A, available at http://www.jem.org/cgi/content/full/ jem.20061631/DC1). As the Thy1.1 + cells were already almost undetectable, it was diffi cult to prove that depletion was successful. However, we could use the same Thy1.1-specifi c antibody to deplete Thy1.1 + cells from control Thy1.2 mice injected with 5 × 10 6 CD4 + Thy1.1 + cells (Fig. S 4 B ).
In addition, CD4 + CD25 high cells were sorted from treated mice, and these T reg cells were able to suppress proliferation of CD4 + CD25 − T cells from BDC2.5 mice when stimulated with anti-CD3 but not with BDC peptide, suggesting that the majority of these cells were not BDC specifi c (unpublished data). Collectively, this suggests that the injected T reg cells were not sustained in large numbers but allowed endogenous T reg cells to maintain a favorable ratio of Foxp3 + cells to Foxp3 − cells.
D I S C U S S I O N Treatment of autoimmunity at late pathogenic stages
Individuals with a high risk for developing diabetes can be identifi ed by genetic markers and the presence of high affi nity islet autoantibodies (32, 33) , and at the time of diagnosis, type 1 diabetes patients retain ‫%01ف‬ of their normal β cell mass (34) . Therefore, inducing T cell tolerance and halting immune-mediated destruction at these two stages of disease may contribute to successful therapy for type 1 diabetes patients. In this study, we addressed T reg cells as inducers of tolerance, but in contrast to most previous studies, we assessed the capacity of T reg cells to treat established autoimmunity rather than prevent it. In the one previous example of natural T reg cells treating spontaneous diabetes, 10 7 isletspecifi c T reg cells were used, an amount almost 10-fold higher than that used in this study (14) . We show that isletspecifi c T reg cells, but not polyclonal T reg cells, can be used to treat autoimmune diabetes in NOD mice months after insulitis has begun and even after overt diabetes has developed. These T reg cells have been expanded in number by DCs presenting a specifi c peptide. This type of expansion of T reg cells by DCs also happens in vivo (9) and represents an important control of the number and, potentially, function of T reg cells.
In the prediabetic mice, CD62L + but not CD62L − T reg cells were able to inhibit diabetes development (Fig. 2) . The CD62L + T reg cells may be more effi cacious, because the CD62L − population may contain more recently activated T cells; alternatively, it is possible that, because CD62L is a homing marker for lymph node traffi cking, the T reg cells must home to lymph nodes to gain effi cacy. Supporting this second possibility, 7 d after transfer of 10 6 Thy1.1 + T reg cells sorted initially on either CD62L + or CD62L − cells, fewer Thy1.1 + cells were found in the pancreatic lymph node of mice injected with CD62L − T reg cells (Fig. 6 C) . Interestingly, CD6L − cells were also found in lower numbers in the pancreas (Fig. 6 D) , suggesting that CD62L is necessary for T reg cells to home fi rst to the lymph node before traffi cking to the infl amed tissue.
Limited evidence exists for the therapeutic role of T reg cells in other autoimmune models. In two diff erent mouse models of colitis induced by injection of pathogenic T cells into lymphopoenic mice, T reg cells given after development of severe intestinal infl ammation could reverse colitis (35, 36) . In experimental autoimmune encephalitis, although transfer of T reg cells has not been shown to reverse disease, spontaneous remission correlated with increased numbers of endogenous T reg cells in the central nervous system, suggesting a role for T reg cells in the natural recovery of established autoimmunity (37) .
Restoration of insulin production in new-onset diabetes
Rescue of insulin production is another important aspect of treatment of diabetes. Islet cell transplant can increase insulin production but requires demanding immunosuppressive drugs to maintain transplantation tolerance. In addition, donors are limited, making this an option for only a small fraction of type 1 diabetic patients (38) . In our experiments, 50% of newly diabetic mice were successfully treated with T reg cells without islet transplant. Interestingly, the T reg celltreated diabetic mice resemble prediabetic mice in both blood glucose levels and response to glucose challenge, suggesting considerable restoration of β cell function. Those mice in which blood glucose remained high may have had too few remaining insulin-producing cells such that even with tolerance induction, these mice would not recover. Signifi cantly lower starting blood glucose levels in mice in which the treatment worked supports the idea that β cell mass, and not tolerance induction, was limiting the success rate of treatment with islet-specifi c T reg cells (Fig. 3 C) .
We also tested the eff ects of GLP-1, because it can increase β cell proliferation and decrease β cell apoptosis, as well as have metabolic eff ects that lower insulin requirements, probably allowing β cells to rest (39) . However, addition of GLP-1 or exendin-4 did not improve the fraction of diabetic mice successfully treated with T reg cells, in contrast to some recently reported fi ndings (5, 40) . One possible explanation for the observed diff erences is that GLP-1 cannot promote diff erentiation from precursors; in this case, if mice did not have enough β cells remaining, GLP-1 would not increase the effi cacy of T reg cell treatment. In addition, the absence of GLP-1 eff ects may be caused by the extremely short in vivo half-life of GLP-1 (41) . Although exendin-4 is more stable in vivo, it is a peptide of nonmammalian origin, and its continuous administration may lead to the production of neutralizing antibodies. New GLP-1 analogues with increased half-lives may help clarify this issue. β cell growth factors may be important for the restoration of endogenous insulin production without islet transplant as long as autoimmunity can be contained with T reg cells. For example, the addition of gastrin, which has also been shown to increase β cell proliferation, may improve the effi cacy of T reg cell treatment of diabetes (42, 43) .
Expansion of T reg cells in diabetic recipients
Diabetic mice treated with T reg cells have higher numbers of Foxp3 + cells in lymph nodes compared with either prediabetic or diabetic NOD females. Although immediately after injection BDC T reg cells divide and expand in the pancreatic lymph node, when examined 50 d after treatment, the increased Foxp3 + cells in the treated mice derive almost entirely from the recipient diabetic mice and not from the injected cells. This was seen in both the pancreatic lymph node and the pancreas. We suspect that the initial expansion of islet-specifi c T reg cells sets up a regulatory environment in the pancreas and draining lymph node that encourages either expansion or diff erentiation of endogenous T reg cells to balance out the increased numbers of pathogenic cells likely found in diabetic mice. The ability of splenocytes from successfully treated mice to transfer diabetes suggests that a dominant, nondeletional tolerance mechanism is important. Interestingly, it was previously shown that transient expression of TGF-β in the pancreas of NOD mice leads to protection for diabetes development and induction of T reg cells (44) .
In some other experimental systems, injected T reg cells are necessary for maintenance of tolerance. For example, antigen-induced Thy1.1 + T reg cells prevent autoimmune ovarian disease. In this system, considerable numbers of the Thy1.1 + T reg cells are maintained long term, but disease returns if the Thy1.1 + T cells are depleted (45) . Similar results
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were found in a mouse model of multiple sclerosis (46) . However, induction of new T reg cells by other T reg cells has been proposed and may involve TGF-β or other cytokines, as has been shown in vitro (47) . In transplantation, anti-CD4 blockade in mice devoid of natural T reg cells leads to acceptance of allogeneic skin grafts. This tolerance is TGF-β dependent and involves the induction of Foxp3 + cells, but doesn't directly show one T reg cell population inducing a new population of T reg cells (48, 49) .
Our fi ndings represent the fi rst demonstration of a defi ned set of natural T reg cells inducing new T reg cells in vivo. The injected T reg cells could have a direct eff ect on expansion or diff erentiation of new T reg cells through cytokine or co-stimulatory molecules. It is also possible that the injected T reg cells "license" the DCs in the pancreas or draining lymph node in a way that improves the ability of these DCs to expand or diff erentiate new T reg cells. These results also show that T reg cells can be expanded from diabetic mice, which may allow the design of antigen-specifi c therapies in new-onset diabetic patients.
In summary, the experiments described in this paper show that T cell tolerance induced by DC-expanded, islet-specifi c T reg cells can both increase endogenous T reg cells and reverse autoimmune diabetes in NOD mice. This antigenspecifi c therapy can now be added to the short list of mostly nonspecifi c methods for reversing diabetes, including anti-CD3 and TGF-β, which may work through induction of T reg cells (50) . These results, in conjunction with our previous report, reiterate the role for DCs in expanding disease-treating T reg cells. Given the fact that DCs expand disease-suppressive, antigen-specifi c T reg cells, a study of these interacting cells could be informative.
MATERIALS AND METHODS
Mice. NOD mice and BDC2.5 TCR transgenic mice on the NOD genetic background were purchased from the Jackson Laboratory and bred under specifi c pathogen-free conditions at the Rockefeller University. Mice of both sexes were used at the indicated ages according to our institutional guidelines. Protocols were approved by the Institutional Animal Care and Use Committee.
Antibodies and staining. Antibodies specifi c for: Gr1 (RB6-8C5), CD4 (H129.19), CD86 (GL1), CD25 (7D4), CD62L (MEL-14), CD25 (PC61), CD4 (RM4-5), and Thy1.1 (OX-7); and isotype controls, 7-aminoactinomycin D, and PE-streptavidin were purchased from BD Biosciences. Streptavidin-Pacifi c blue was purchased from Invitrogen. Anti-Foxp3 (FJK-16s) conjugated to PE or APC was purchased from eBioscience. A hybridoma expressing the anticlonotype antibody specifi c for the BDC2.5 TCR (BDC) was provided by O. Kanagawa (Washington University, St. Louis, MO), and the antibody was purifi ed and biotinylated. All staining was done according to standard protocols.
Purifi cation and DC-based expansion of regulatory cells. Bone marrow-derived DCs from NOD mice were matured with LPS and enriched for CD86 + cells using magnetic beads, as described previously (9) . T cells were purifi ed from lymph nodes and spleens from BDC2.5 NOD mice by fi rst labeling with anti-CD4-FITC, CD62L-APC, and CD25-biotin, followed by streptavidin-PE and enriching for CD25 + cells with magnetic beads coated with PE-specifi c antibodies (Miltenyi Biotec). CD4 + CD25 + CD62L + or CD4 + CD25 + CD62L − cells were then sorted to >98% purity. The T cells and DCs were cultured at a ratio of 1:1, as previously described (9), for 6-8 d with 100 ng/ml BDC mimetope peptide (termed 1040-55; sequence R V R P L W V R M E ) (12) and 200 U/ml rHuIL2 (Chiron Corp). Unless otherwise indicated, the T reg cells used in this study are CD4 + CD25 + CD62L + cells from BDC2.5 NOD mice expanded with DCs.
Diabetes experiments. Treatment of prediabetic mice was as follows. 13-wk-old nondiabetic female NOD mice were given the numbers of DCexpanded T reg cells via i.v. injection indicated in the fi gures, and diabetes was monitored by urine glucose once per week. Diabetes was defi ned as three consecutive positive readings.
Treatment of diabetic NOD mice was as follows. To have an average of 5-10 newly diabetic mice at any one time, we have followed a cohort of ‫003-002ف‬ NOD females between 12-30 wk old. Diabetic NOD females were identifi ed by urine glucose and confi rmed by a blood glucose reading >250 mg/dl. Within each experiment, these starting blood glucose levels were matched between groups. Insulin pellets were then implanted s.c. as needed to maintain blood glucose <250 mg/dl for 40 d and removed. Each pellet contains 13 mg of insulin and continuously releases ‫1.0ف‬ unit/ implant (LinShin Canada, Inc.). In the groups indicated, mice were injected on days 0 and 14 with 0.8-1.5 × 10 6 BDC T reg cells by i.v. injection and with 50 ng exendin-4 (Bachem) on days 0, 1, 2, 7, 8, and 9 by i.p. injection. The subsequent development of diabetes was monitored by blood glucose readings two to three times per week. All mice denoted in the fi gures as responders, successfully treated, or T reg treated were followed for a minimum of 2 mo and for as long as 6 mo after removal of exogenous insulin. For the experiment shown in Fig. 3 A, NOD females with diabetes were identifi ed by urine glucose within 5 d of onset and given insulin via pellets that secrete continuously for ‫3ف‬ wk. All mice received i.p. injection of 5 μg GLP-1 (Bachem) on days 2, 3, 5, 11, 16, 23, 25, and 29. Within 3 d of receiving the insulin pellet, one group was injected i.v. with 1.5 × 10 6 DC-expanded CD4 + CD25 + CD62L + cells isolated from BDC2.5 mice.
Depletion with anti-Thy1.1. 100 μg anti-Thy1.1 (clone HIS51) was given i.v., and expression of Thy1.1 after depletion was monitored using anti-Thy1.1 (clone OX-7) at the times indicated in the fi gures.
Glucose tolerance test. Mice were kept without food for 15 h and were given 2 mg of glucose per gram of bodyweight i.p. Blood glucose was monitored at the intervals indicated in Fig. 4 A for 90 min.
Histology. Insulitis and sialitis were checked by observing lymphocytic infi ltrates in the pancreatic islets or salivary glands using hematoxylin and eosin sections. Insulitis was scored as follows: no insulitis, periinsulitis, intrainsulitis with <70% of the islet infi ltrated, or intrainsulitis with >70% of the islet infi ltrated.
Immunofl uorescence. Tissue was frozen in optimal cutting temperature compound. 10-μm sections were air dried and fi xed in acetone. Sections were stained with anti-Thy1.1-FITC (Ox-7), anti-FITC-Alexa Fluor 488 (Invitrogen), Foxp3-PE, anti-rat-Alexa Fluor 546 (Invitrogen), and CD4-Alexa Fluor 647 (L3T4; BD Biosciences) or isotype controls and blocked with 5% mouse serum and 2-5% rat serum. Images were acquired on an inverted laser scanning confocal microscope (LSM 510; Carl Zeiss MicroImaging, Inc.) using a 40× objective. Fig. 3 D were analyzed by Fisher's exact test. Groups in Fig. 2 were compared by the Mann-Whitney U test. Groups in Fig. 3 C, Fig. 4 B, and Fig. 5 B were compared using a t test.
Statistics. Comparisons of groups in
Online supplemental material. Fig. S1 shows an additional example of treatment of diabetic mice with T reg cells and exendin-4. Fig. S2 shows blood glucose levels of female NOD mice from 13 to 25 wk of age. Fig. S3 shows insulitis levels in T reg cell-treated diabetic mice. Fig. S4 shows the results of depletion of Thy1.1 + cells with anti-Thy1.1. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20061631/DC1.
